XPO1 and hepatocellular carcinoma: An in vitro study demonstrated that a Selinexor-derived synthetic inhibitor suppressed dose-dependent cell proliferation, promoted apoptotic pathways in hepatocellular carcinoma cells with suppressing CRM1 protein function [45].